the immunopotentiator

Sures of genital when used with podophyllin or carbon dioxide laser



Effectively treats genital herpes



Accelerates healing of herpes labialis

the body's ally against viral infection



Prescribing Information

Principal Action: Imunovir is an agent demonstrating anti-viral activity and possessing immunopotentiating action in viral diseases. Dosage: Herpes simplex: two tablets q.d.s. for 7 to 14 days. Genital warts: two tablets t.d.s. for 14 to 28 days. (See Indications). Presentation: Each tablet contains 500 mg inosine pranobex. Indications: Management of mucocutaneous infections due to herpes simplex virus (type I and/or type II) and management of genital warts when used with podophyllin or carbon dioxide laser. Contra-indications: None known. Precautions: Patients with renal impairment, a history of gout or

hyperuricaemia. Pregnancy. Side effects: Rare and usually of a mild and transitory nature. Only commonly associated adverse effect is transient raised uric acid levels. Overdose: No experience. Treatment should be restricted to symptomatic and supportive measures. Product Licence No.: 0748/0049. Basic N.H.S. Price: 100 £37.24.

Edwin Burgess, A Division of Scanpharm Ltd., Longwick Road, Princes Risborough, Aylesbury, Bucks HP17 9RR.

Trademark of the Licensor, Newport Pharmaceuticals Int. Inc.



This is a subjective and insensitive method, for observing the presence of candida in vaginal swab specimens, which has long been recognised to require confirmation by culture, producing a result *after* treatment has been prescribed.

time taken 48 hrs

*Candidate Super – more sensitive and easier to interpret than microscopy.

Candidate Super – Extensive trials in two leading clinics of genito-urinary medicine have also shown that CANDIDATE SUPER has a predictive positive value almost twice that obtained from culture isolation.

Candidate Super – in the clinic. As part of the routine of the busy clinic Candidate Super provides the right answers at the right time – before treatment is prescribed. Fewer patient follow-up visits reduces workload and reduces cost.

Candidate Super—in the surgery. Simple and reliable, CANDIDATE SUPER requires no training to perform and provides results in minutes causing no delay in patient turnround times.

^{*} Candidate is a registered trademark



WHAT'S THIS?



This is a rapid and simple patient side diagnostic test for vulvo vaginal candidosis which detects candida from vaginal swab specimens and does not require culture confirmation. Results are available *before* treatment is prescribed.

time taken 5 mins

Candidate Super—in the laboratory. The flexible packaging concept of CANDIDATE SUPER allows the separation of the 'specimen collection pack' from the 'test pack' to suit any circumstances. Laboratory results indicate that Candidate Super, unlike culture, demonstrates excellent differentiation between candida overgrowth and commensal carriage.

Candidate Super—is emerging as the most accurate, single diagnostic criterion for the management of vaginal candidosis.

CANDIDATE SUPER

Mercia diagnostics

Mercia Diagnostics Limited, Brocades House, Pyrford Road, West Byfleet, Surrey KT14 6RA, UK. Telephone: Byfleet 42291. Telex: 917301.

1 IS ENOUGH

BAIER

3-day action against thrush in a single tablet

Canesten 1

"Treatment of vaginal candidosis with a single 500-mg clotrimazole pessary [Canesten 1] was found to be as effective as previous treatment regimens of longer duration."

Br J Ven Dis 1982;58:124-6.

Prescribing information: Presentation: Canesten 1 is available as a single 500mg vaginal tablet with applicator. Dosage: A single vaginal tablet to be inserted preferably at night. Side effects: Rarely patients may experience transient local mild burning or irritation. Basic NHS Cost: 1x 500mg vaginal tablet with applicator, 52.58. Product Licence Number: Vaginal Tablets 500mg, PL0010/0083.



Further information is available from: Bayer UK Limited Pharmaceutical Division Bayer House Strawberry Hill Newbury Berkshire RG13 UA Telephone: Newbury (0635) 39000 @Registered trade mark of Bayer, Germany

MSSVD

The Medical Society for the Study of Venereal Diseases

President: Dr J D Oriel
University College Hospital, London WC1E 6AU

The object of the Society is to bring together those interested or engaged in the diagnosis, treatment, and community medical aspects of sexually transmitted diseases. The Society meets regularly in London at the Royal Society of Medicine for the reading of papers, discussions, and presentation of cases. An out-of-London meeting is held in the Spring.

Annual subscription for membership of the Society is £50 for all members. Applications for membership are very welcome and forms can be obtained from the Honorary Secretary, Dr M A Waugh, Department of Genito-Urinary Medicine, The General Infirmary, Great George Street, Leeds LS1 3EX.

Please note - all correspondence regarding MSSVD to Hon. Sec.

PROGRAMME 1986 - 1987

Royal Society of Medicine, 1 Wimpole Street, London W1M 8AE

A G M 31st October 1986 6.45pm followed by Short Papers.

28 November 1986 Ordinary General Meeting 7 pm. New methods of diagnosis of cervical and vaginal conditions

- Dr Dulcie Coleman, St Mary's Hospital, London. The diagnosis of Sexually Transmitted Diseases in women as seen by the Cytologist.
- 2. Professor C Easmon, St Mary's Hospital, London - Non-specific vaginitis.
- 3. Dr G Evans, University of Leeds Candidiasis.

30th January 1987 Ordinary General Meeting 7 pm. Rape and Child Sexual Abuse

- 1. Dr R E I Roberts, Manchester Rape, How the Physician handles it.
- Det Chief Superintendent Thelma Wagstaff, London - Rape: The management by the police of rape victims.
- Dr Jane Wynne & Dr C Hobbs, Leeds Child Sexual Abuse.

 Dr Greta Forster, London - A study of STD in rape victims.

27th February 1987 Ordinary General Meeting 7 pm. Short Cases and other items of topical interest.

27th March 1987 Ordinary General Meeting 7 pm. Recent Advances in Syphilis.

- Dr T Riordan, Manchester Screening Tests: Evaluation in low prevalence screening.
- Dr H Young, Edinburgh Screening Tests: evaluation in clinical practice and high risk groups.
- 3. Dr C Penn, Birmingham Research into Treponematoses.

24th April 1987 Presidential Address 7 pm.

14-17th May 1987 Spring Meeting of MSSVD with corresponding Dutch and Belgian Societies, Antwerp, Belgium.

New Tetralysal

At the forefront of anti-chlamydial therapy

■ Proven high efficacy against NGU and mixed urethritis 1,2

- Excellent record of gastrointestinal ³ and oesophageal ^{3,4} tolerance
- No reported photosensitivity 5
- Simple b.d. dosage
- Economical



References. 1. Ghosen V et al. Proc Int Symp Rome, Oct 1979. (Farmitalia Carlo Erba S.p.A., Milan 1980). pp 83-85. 2. Wallin J et al. Proc Int Symp Rome, Oct 1981. (Farmitalia Carlo Erba S.p.A., Milan 1982). pp 91-94. 3. Kollberg L. Proc Int Symp Rome, Oct 1979 (op cit). pp 69-76. 4. Carlborg BI, Densert O, Lindqvist CK. Proc Int Symp Rome, Oct 1981 (op cit). pp 105-109. 5. Bjellerup M, Ljunggren B. J Invest Dermatol 1985; 84: 262-264.

Prescribing Information. Name of Product: Tetralysal® 300. Presentation: Tetralysal® 300 is available as white, hard gelatin capsules containing 408mg of lymecycline BP equivalent to 300mg tetracycline base. Uses: All conditions where tetracycline therapy is indicated, including non-gonococcal urethritis of chlamydial origin and other chlamydial infections such as trachoma. Dosage and Administration: The usual recommended dose is 1 capsule bd. If higher doses are required 3-4 capsules may be given over 24 hours. In the management of sexually transmitted disease both partners should be treated. Contra-Indications, Warnings, etc: Tetralysal® 300 should not be administered to pregnant women or children below the age of 8 years, nor to patients with overt renal insufficiency or those hypersensitive to tetracyclines. The absorption of tetracyclines may be affected by the simultaneous administration of antacids and iron preparations. Basic NHS Price: Bottles of 20 and 100 capsules at £2.46 and £12.30. Product Licence Number: 3493/0044.

Further information is available on request from:



HOW TO DO IT

SECOND EDITION

The first edition of HOW TO DO IT proved a useful and popular guide to those things a doctor needs to know but is rarely taught: how to take an examination, how to interview and be interviewed, how to plan and write up research, how to behave at an inquest. In the second edition the original chapters have been expanded and updated, and there are several more chapters on new challenges—choosing a computer, flying, holding a press conference—and on some older ones not included in the first edition—assessing a job, dealing with a publisher.

Price: Inland £6.95 Abroad £9.00/USA \$14.50 BMA members: Inland £6.45 Abroad £8.50/USA \$13.50 including postage, by air abroad

Please quote membership number

Payment must be enclosed with order

Order from
The Publishing Manager
British Medical Journal
BMA House, Tavistock Square
London WC1H 9JR
or any leading bookseller

